Trade and Investment Queensland and Australian Trade and Investment Commission Strengthen India Ties at BioAsia 2026

manufacturing-news

Trade and Investment Queensland (TIQ), the Queensland Government’s international business arm, in collaboration with the Australian Trade and Investment Commission (Austrade), wrapped up a high-impact visit to BioAsia 2026, Asia’s leading life sciences and biotechnology gathering hosted annually by the Government of Telangana, India.

Guided by the Queensland Government’s “QueensLand of Opportunity” agenda, the delegation highlighted the state’s expertise in biotechnology-led drug discovery, clinical research, and digital health innovation. Meetings and industry interactions across Hyderabad and Bengaluru connected Queensland representatives with India’s fast-growing innovation landscape, opening avenues for expanded research alliances, commercial collaborations, and cross-border investments.

India offers significant expansion potential for Australian organisations in areas such as vaccine research, cell and gene therapies, clinical development services, and medical technology. Australia continues to be regarded as a reliable destination for Indian biopharma and MedTech companies seeking efficient clinical trial start-ups and globally accepted data, particularly for early-stage studies.

The programme featured participation in the BioAsia conference and exhibition, a focused Clinical Trials Roundtable, and curated business-to-business meetings aimed at building partnerships and enhancing bilateral market understanding.

Abhinav Bhatia, Senior Trade & Investment Commissioner – South Asia, Trade and Investment Queensland, said India’s evolution from large-scale pharmaceutical manufacturing to high-value innovation creates strong alignment with Queensland’s research capabilities. He noted that Queensland’s established research infrastructure and competitive R&D tax incentives can complement India’s manufacturing strengths to accelerate the development and delivery of next-generation therapies.

Mary Overington, Trade and Investment Commissioner at the Australian Trade and Investment Commission, added that the engagement underscored the natural synergy between Australia’s research-driven ecosystem and India’s scale in clinical research and production. Through targeted discussions and stakeholder meetings, the delegation identified practical collaboration pathways in clinical trials, biotechnology research, and life sciences manufacturing, reflecting growing industry interest in deeper commercial ties.

With both India and Queensland focused on advancing healthcare systems and high-value manufacturing, the mission is expected to catalyse new investment flows and expand scientific cooperation across the health and life sciences sectors.